Abstract: Methods, apparatuses and wearable devices for measuring an ECG signal for a user wearing a wearable device includes when the ECG signal is measured in a first mode, receiving the ECG signal by an ECG sensor from a closed circuit formed by a first ECG sensor electrode and a second ECG sensor electrode, in which the wearable device includes a main body detachable to the wearable device, a connecting portion, and electrode patches, and the main body includes the ECG sensor, the first ECG sensor electrode, and the second ECG sensor electrode, and when the ECG signal is measured in a second mode, receiving the ECG signal by the ECG sensor from a closed circuit formed by electrodes of the electrode patches, in which the ECG sensor is in the main body and the main body is connected to the electrode patches.

Abstract: A preparation containing a chlorogenic acid crystal form. The crystal form is an orthorhombic crystal system, a space group is P212121, cell parameters are as follows: a=7.7291(2)?, b=10.9808(2)?, c=36.5334(7)?, ?=?=?=90.00°, Z=8, and a cell volume is 3100.65(11)?3. The content of the chlorogenic acid crystal form in the preparation is 10-5000 mg/g. The preparation is advantageous to bioavailability, and can be used for preparing medicines for treating tumor, psoriasis and other immune system diseases, resisting oxidation, protecting liver and gallbladder, treating cardiovascular diseases, and resisting viruses.

Abstract: The present invention provides an application of chlorogenic acid in preparing medicines for treating melanoma and a pharmaceutical composition comprising chlorogenic acid and used for treating melanoma.

Abstract: Provided is a crystalline form of chlorogenic acid. The crystalline form is an orthorhombic crystal system, the space group is P212121, the cell parameters are a=7.7291 (2) ?, b=10.9808 (2) ?, and c=3.5334 (7) ?, ?=?=?=90.00°, Z=8, and the cell volume is 3100.65 (11) ?3. Also provided is a preparation method for the crystalline form. The present crystalline form has good stability and does not significantly change during storage for 48 months in a cool, dark place, and the various indices all meet the relevant requirements for active pharmaceutical ingredients. The crystallization process provided by the present invention can not only use raw materials having different purities to prepare the same crystalline form of chlorogenic acid, but can also significantly reduce solvent residue in the raw materials, thereby improving product safety.

Abstract: The pharmaceutical composition is a formulation prepared by the raw materials in parts by weight: 1-300 parts of chlorogenic acid and 1-50 parts of Ganoderma lucidum spore oil, and the preparative process for said pharmaceutical composition was provided. Chlorogenic acid can be used compatibly with Ganoderma lucidum spore oil, with a synergistic effect. Inclusion technique is applied in product development to improve stability of oily liquid material Ganoderma lucidum spore oil and solid material chlorogenic acid obtained from the extract of Eucommia leaves. After inclusion by the inclusion technology, the liquid drugs become powder, and thus easily oxidized natural products could be protected. Moreover, the damage for active ingredients caused by air can be prevented, and the stability and the taste may get improved.

Abstract: Methods and apparatuses for adjusting a game scene are set forth herein. The method includes receiving heart rate information of a user, wherein the user wears the computing device to play the game, and based on the received heart rate information of the user, adjusting at least one element in the game scene of the game. By using a smart wearable device to acquire the heart rate information of the user playing the game, the game scene of the game can be adjusted according to the heart rate information. Therefore, the game can be made to be more interesting by receiving multi-dimensional interaction information of the user.

Abstract: The present invention provides one method for the preparation of pharmaceutically acceptable chlorogenic acid, which comprises the following steps: a. Treating the sample aqueous solution; b. Freezing; c. Thawing and filtering; d. Treating the residue organic phase; e. Concentrating and crystallizing; f. Choosing the number of times to repeat steps a-e according to the variability of chlorogenic acid content in samples; g. Drying. If the chlorogenic acid extract is isolated and purified using this method, water-soluble impurities and liposoluble impurities can be well removed, that allows the impurity content of final products has fulfilled the requirements for medicine; meanwhile, the procedures of this method are simple, and organic solvents can be recycled for further use, with low cost. This method can be applied for the further isolation and purification of chlorogenic acid extract obtained by various ways, especially for the preparation of pharmaceutically acceptable chlorogenic acid.

Abstract: An organic electroluminescence device includes: a substrate; a switching layer disposed on the substrate, and the switching layer includes multiple switching elements arranged as a matrix; an organic electroluminescence layer disposed on the switching layer, the organic electroluminescence layer includes multiple organic electroluminescence elements arranged as a matrix, the organic electroluminescence elements are controlled to emit light through corresponding switching elements; a first planarization layer disposed on the substrate, covering on the switching layer and the organic electroluminescence layer; and a touch layer disposed on the substrate and covering on the first planarization layer. The present invention also provides a manufacturing method for the organic electroluminescence device. Using the first planarization layer to directly encapsulate the switching layer and the organic electroluminescence layer, and no additional Thin Film Encapsulation layer is required.

Abstract: The present invention provides an application of chlorogenic acid in preparing medicines for treating lupus erythematosus. The chlorogenic acid can improve an immunity function. The present invention provides a preparation for treating lupus erythematosus, comprising chlorogenic acid and pharmaceutically acceptable auxiliary materials. The present invention further provides a combined medicine comprising chlorogenic acid and medicines for treating lupus erythematosus.

Abstract: A method includes: receiving sensor data representing a subject within a field of vision associated with respective ones of a plurality of modular cameras associated with a composite camera and one or more geo-spatial characteristics associated with respective ones of the plurality of modular cameras; determining an arrangement of the composite camera based on the sensor data; generating digital content for respective ones of the plurality of modular cameras based on the sensor data; and generating combined digital content that represents a subject within a field of vision associated with the composite camera based on the digital content and the arrangement of the composite camera, wherein the field of vision associated with the composite camera includes at least some of fields of vision associated with the plurality of modular cameras.

Abstract: A method, an apparatus, and a system for pushing network content includes receiving an identity of a user and a current status parameter of the user, acquiring user information associated with the identity including personal information of the user and a browsing history of the user, selecting network content according to the status parameter and the user information, and pushing the network content to a terminal device configured to display the network content.

Abstract: The present invention provides a chlorogenic acid powder-injection. The chlorogenic acid powder-injection is prepared from the following raw materials in parts by weight: 1-120 parts of chlorogenic acid, 1-320 parts of a bracket agent and 1-8 parts of an antioxidant. The present invention further provides a preparation method of the powder-injection. The chlorogenic acid powder-injection provided in the present invention is good in stability, strong in re-solubility and safe in clinical use.

Abstract: The present invention provides an application of chlorogenic acid in preparing medicines for treating melanoma and a pharmaceutical composition comprising chlorogenic acid and used for treating melanoma.

Abstract: The present invention provides an application of chlorogenic acid in preparing medicines for treating lupus erythematosus. The chlorogenic acid can improve an immunity function. The present invention provides a preparation for treating lupus erythematosus, comprising chlorogenic acid and pharmaceutically acceptable auxiliary materials. The present invention further provides a combined medicine comprising chlorogenic acid and medicines for treating lupus erythematosus.

Abstract: Disclosed are a eucommia leaf extract, and preparation method and use thereof. The extract is a liquid of the eucommia leaf or an ethyl alcohol extract, and has chlorogenic acid of a content not less than 9%, geniposidic acid of a content not less than 1% and aucubin of a content not less than 1%. The extract has a good effect on psoriasis.

Abstract: A method for processing electrocardiograph (ECG) data using a garment includes determining, by a processor, a current working lead from ECG leads formed in advance using flexible electrodes in the garment based on a current ECG monitor type, and receiving, by the processor through lead wires corresponding to the current working lead, ECG data collected by flexible electrodes corresponding to the current working lead. A wearable apparatus for processing ECG data includes at least two flexible electrodes, in which the at least two flexible electrodes are capable of forming different leads based on predetermined configurations, at least two lead wires, and an ECG data collector configured to receive ECG data collected by the at least two flexible electrodes, in which each of the at least two flexible electrodes connects to the ECG data collector via at least one of the at least two lead wires.

Abstract: The present invention provides one method for the preparation of pharmaceutically acceptable chlorogenic acid, which comprises the following steps: a. Treating the sample aqueous solution; b. Freezing; c. Thawing and filtering; d. Treating the residue organic phase; e. Concentrating and crystallizing; f. Choosing the number of times to repeat steps a-e according to the variability of chlorogenic acid content in samples; g. Drying. If the chlorogenic acid extract is isolated and purified using this method, water-soluble impurities and liposoluble impurities can be well removed, that allows the impurity content of final products has fulfilled the requirements for medicine; meanwhile, the procedures of this method are simple, and organic solvents can be recycled for further use, with low cost. This method can be applied for the further isolation and purification of chlorogenic acid extract obtained by various ways, especially for the preparation of pharmaceutically acceptable chlorogenic acid.

Abstract: A preparation containing a chlorogenic acid crystal form. The crystal form is an orthorhombic crystal system, a space group is P212121, cell parameters are as follows: a=7.7291(2)?, b=10.9808(2)?, c=36.5334(7)?, ?=?=?=90.00°, Z=8, and a cell volume is 3100.65(11)?3. The content of the chlorogenic acid crystal form in the preparation is 10-5000 mg/g. The preparation is advantageous to bioavailability, and can be used for preparing medicines for treating tumor, psoriasis and other immune system diseases, resisting oxidation, protecting liver and gallbladder, treating cardiovascular diseases, and resisting viruses.

Abstract: Methods, apparatuses and wearable devices for measuring an ECG signal for a user wearing a wearable device includes when the ECG signal is measured in a first mode, receiving the ECG signal by an ECG sensor from a closed circuit formed by a first ECG sensor electrode and a second ECG sensor electrode, in which the wearable device includes a main body detachable to the wearable device, a connecting portion, and electrode patches, and the main body includes the ECG sensor, the first ECG sensor electrode, and the second ECG sensor electrode, and when the ECG signal is measured in a second mode, receiving the ECG signal by the ECG sensor from a closed circuit formed by electrodes of the electrode patches, in which the ECG sensor is in the main body and the main body is connected to the electrode patches.